Tekla Life Sciences Investors
Tekla Life Sciences Investors (HQL) Revenue
Annual & quarterly revenue history · segment & region breakdown
HQL · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsTekla Life Sciences Investors trailing twelve-month (TTM) revenue is $0.03B, a decrease of 0.35% year-over-year from $0.09B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-09-30 | $0.09B | -$0.00B | -0.35% |
| 2024-09-30 | $0.09B | +$0.05B | +120.10% |
| 2023-09-30 | $0.04B | +$0.01B | +23.61% |
| 2022-09-30 | $0.03B | -$0.01B | -29.23% |
| 2021-09-30 | $0.05B | +$0.01B | +15.23% |
| 2020-09-30 | $0.04B | +$0.04B | +1500.91% |
| 2019-09-30 | $0.00B | +$0.00B | +22.90% |
| 2018-09-30 | $0.00B | -$0.07B | -97.16% |
| 2017-09-30 | $0.07B | +$0.06B | +1009.65% |
| 2016-09-30 | $0.01B | +$0.00B | +375.68% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Tekla Life Sciences Investors receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Tekla Life Sciences Investors reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Tekla Life Sciences Investors's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
HQL revenue · 4 questionsHQL's trailing twelve-month (TTM) revenue is $0.03B. That is a decrease of 0.35% year-over-year from $0.09B in FY2025.
▸ Source: FMP · Tekla Life Sciences Investors SEC filings · GAAP · Tekla Life Sciences Investors SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026